Protocol
13-072
Full Title
An Open-Label Phase II Study of BKM120 in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma
Purpose
Despite conventional treatment approaches, such as chemotherapy and radiation therapy, lymphoma persists in many patients. Therefore, the treatment for relapsed lymphoma remains challenging. The purpose of this study is to evaluate the safety and effectiveness of BKM120 in patients with diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma that has persisted or returned despite prior therapy.
BKM120 is an investigational drug designed to inhibit cancer growth by blocking PI3 kinase (PI3K), an enzyme which drives the growth and survival of some types of cancer, including hematologic cancers such as lymphoma. BKM120 is a pill that is taken orally (by mouth).
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma that has returned or persisted after receiving at least one prior regimen of therapy.
- At least 4 weeks must have passed since completion of prior therapy and entry into the study.
- Patients who have previously received PI3K inhibitors may not participate.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- This study is open to patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Anas Younes at 212-639-7715 or Amy Copeland, Research Clinical Nurse Specialist, at 212-639-6104.
Disease(s)
Lymphoma: Non-Hodgkin's Lymphoma
Locations
Related Diseases
